Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03259308




Registration number
NCT03259308
Ethics application status
Date submitted
21/08/2017
Date registered
23/08/2017
Date last updated
26/04/2021

Titles & IDs
Public title
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Scientific title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Secondary ID [1] 0 0
2017-000572-28
Secondary ID [2] 0 0
SHP647-302
Universal Trial Number (UTN)
Trial acronym
FIGARO UC 302
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ontamalimab
Treatment: Drugs - Placebo

Experimental: Ontamalimab 25 mg - Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.

Experimental: Ontamalimab 75 mg - Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.

Placebo comparator: Placebo - Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.


Treatment: Drugs: Ontamalimab
Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Treatment: Drugs: Placebo
Participants will receive 1 mL of sterile aqueous buffered solution.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Remission Based on Composite Score at Week 12
Timepoint [1] 0 0
At Week 12
Secondary outcome [1] 0 0
Number of Participants With Endoscopic Remission at Week 12
Timepoint [1] 0 0
At Week 12
Secondary outcome [2] 0 0
Number of Participants With Clinical Remission at Week 12
Timepoint [2] 0 0
At Week 12
Secondary outcome [3] 0 0
Number of Participants With Clinical Response Based on Composite Score at Week 12
Timepoint [3] 0 0
At Week 12
Secondary outcome [4] 0 0
Number of Participants With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12
Timepoint [4] 0 0
At Week 12
Secondary outcome [5] 0 0
Number of Participants With Remission Based on Total Mayo Score at Week 12
Timepoint [5] 0 0
At Week 12
Secondary outcome [6] 0 0
Number of Participants With Clinical Response Based on Total Mayo Score at Week 12
Timepoint [6] 0 0
At Week 12
Secondary outcome [7] 0 0
Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12
Timepoint [7] 0 0
At Weeks 4, 8, and 12
Secondary outcome [8] 0 0
Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8
Timepoint [8] 0 0
At Weeks 4 and 8
Secondary outcome [9] 0 0
Number of Participants With Endoscopic Remission With Sub-score of 0 at Week 12
Timepoint [9] 0 0
At Week 12
Secondary outcome [10] 0 0
Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Sub-scores of 0 at Weeks 4, 8, and 12
Timepoint [10] 0 0
At Weeks 4, 8, and 12
Secondary outcome [11] 0 0
Number of Participants With Deep Remission at Week 12
Timepoint [11] 0 0
At Week 12
Secondary outcome [12] 0 0
Change From Baseline in Average Worst Abdominal Pain Score Based on Patient Reported Outcome-ulcerative Colitis (PRO-UC) Daily e-Diary at Week 12
Timepoint [12] 0 0
Baseline, Week 12
Secondary outcome [13] 0 0
Change From Baseline in Diarrhea (Average Loose Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12
Timepoint [13] 0 0
Baseline, Week 12
Secondary outcome [14] 0 0
Change From Baseline in Average Bowel Movements With Urgency Score Based on PRO-UC Daily e-Diary at Week 12
Timepoint [14] 0 0
Baseline, Week 12
Secondary outcome [15] 0 0
Change From Baseline in Absolute Stool Frequency (Average Number of Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12
Timepoint [15] 0 0
Baseline, Week 12
Secondary outcome [16] 0 0
Change From Baseline in Absolute Rectal Bleeding (Average Number Bowel Movements With Blood) Score Based on PRO-UC Daily e-Diary at Week 12
Timepoint [16] 0 0
Baseline, Week 12
Secondary outcome [17] 0 0
Change From Baseline in Total Sign/Symptom Score Based on PRO-UC Daily e-Diary at Week 12
Timepoint [17] 0 0
Baseline, Week 12
Secondary outcome [18] 0 0
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains Scores at Weeks 8 and 12
Timepoint [18] 0 0
Baseline, Weeks 8 and 12
Secondary outcome [19] 0 0
Change From Baseline in IBDQ Total Scores at Weeks 8 and 12
Timepoint [19] 0 0
Baseline, Weeks 8 and 12
Secondary outcome [20] 0 0
Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores) at Week 12
Timepoint [20] 0 0
Baseline, Week 12
Secondary outcome [21] 0 0
Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Individual Domain Scores) at Week 12
Timepoint [21] 0 0
Baseline, Week 12
Secondary outcome [22] 0 0
Number of Participants Based on Inpatient Hospitalization
Timepoint [22] 0 0
From start of study up to follow up (Week 29)
Secondary outcome [23] 0 0
Median Duration of Total Inpatient Days
Timepoint [23] 0 0
From start of study up to follow-up (Week 29)

Eligibility
Key inclusion criteria
- Participants and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.

* Participants must be able to voluntarily provide written, signed, and dated informed consent and/or assent, as applicable, to participate in the study.
* Participants less than (<) 18 years of age must weigh >=40 kg and must have body mass index (BMI) >=16.5 kilogram per square metre (kg/m^2).
* Participants must have a documented diagnosis of UC for >=3 months before screening. The following must be available in each participant's source documentation:

a. A biopsy report to confirm the histological diagnosis. b. A report documenting disease duration based upon prior colonoscopy. Note: If this documentation is not available at the time of screening, a colonoscopy with biopsy to confirm the diagnosis is required during the screening period.
* Participants must be willing to undergo a flexible sigmoidoscopy or colonoscopy, including biopsy sample collection, during screening after all other inclusion criteria have been met.
* Participants must have moderate to severe active UC, defined as a total Mayo score of >=6, including a centrally read endoscopic subscore >=2, rectal bleeding subscore >=1, and stool frequency subscore >=1 at baseline.
* Participants must have evidence of UC extending proximal to the rectum (ie, not limited to proctitis).
* Participants must have had an inadequate response to, or lost response to, or had an intolerance to at least 1 conventional treatment such as mesalamine (5-aminosalicylate [ASA]), glucocorticoids, immunosuppressants (azathioprine [AZA], 6-mercaptopurine [6-MP], or methotrexate [MTX]), or anti-tumor necrosis factor (TNF).
* Participants receiving any treatment(s) for UC are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period of time.
* Participants are males or nonpregnant, nonlactating females who, if sexually active, agree to comply with the contraceptive requirements of the protocol, or females of nonchildbearing potential.
Minimum age
16 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants with indeterminate colitis, microscopic colitis, non-steroidal anti-inflammatory drug-induced colitis, ischemic colitis, infectious colitis, or clinical/histologic findings suggestive of Crohn's disease.
* Participants with colonic dysplasia or neoplasia. (Participants with prior history of adenomatous polyps will be eligible if the polyps have been completely removed.)
* Participants with past medical history or presence of toxic megacolon.
* Participants with colonic stricture, past medical history of colonic resection, a history of bowel surgery within 6 months before screening, or who are likely to require surgery for UC during the treatment period.
* Participants at risk for colorectal cancer must have a colonoscopy performed during the screening period with results available within 10 days before the baseline visit, unless the participant has had a surveillance colonoscopy performed within 1 year prior to screening, and any adenomatous polyps found at that examination have been excised. Colonoscopy report and pathology report (if biopsies are obtained) from the colonoscopy performed during screening or in the prior year confirming no evidence of dysplasia and colon cancer must be available in the source documents.

Participants at risk for colorectal cancer include, but are not limited to:

1. Participants with extensive colitis for >=8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >=10 years before screening, regardless of age.
2. Participants >=50 years of age at the time of signing of the informed consent form.

- Participants have had prior treatment with ontamalimab (formerly PF-00547659, SHP647).

- Participants with known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients.

- Participants have received anti-TNF treatment within 60 days before baseline.

- Participants have received any biologic with immunomodulatory properties (other than anti-TNFs) within 90 days before baseline.

- Participants have received any nonbiologic treatment with immunomodulatory properties (other than their current background UC treatment) within 30 days before baseline.

- Participants have ever received anti-integrin/adhesion molecule treatment (example (eg): natalizumab, vedolizumab, efalizumab, etrolizumab, or any other investigational anti-integrin/adhesion molecule).
* Participants have received parenteral or rectal glucocorticoids, or rectal 5-ASA, within 14 days before screening endoscopic procedure.
* Participants have received leukocyte apheresis or selective lymphocyte, monocyte, or granulocyte apheresis or plasma exchange within 30 days before baseline.
* Participants have participated in other investigational studies within either 30 days or 5 half-lives of investigational product used in the study (whichever is longer) before baseline.
* Participants have received a live (attenuated) vaccine within 30 days before the baseline visit.
* Participants with active enteric infections (positive stool culture and sensitivity), Clostridium difficile infection or pseudomembranous colitis [Participants with C. difficile infection at screening may be allowed re-test after treatment], evidence of active cytomegalovirus infection or Listeria monocytogenes, known active invasive fungal infections such as histoplasmosis or parasitic infections, clinically significant underlying disease that could predispose the participants to infections, or a history of serious infection (requiring parenteral antibiotic and/or hospitalization) within 4 weeks before the baseline visit.
* Participants with abnormal chest x-ray findings at screening, such as presence of active tuberculosis (TB), general infections, heart failure, or malignancy.
* Participants with evidence of active or latent infection with Mycobacterium TB or participants with this history who have not completed a generally accepted full course of treatment before randomization are excluded. All other participants must have either the Mantoux (purified protein derivative [PPD]) tuberculin skin test or interferon gamma release assay (IGRA) performed.

Participants who have no history of previously diagnosed active or latent TB are excluded if they have a positive Mantoux (PPD) tuberculin skin test (ie >=5 millimeter [mm] induration) or a positive IGRA (the latter to be tested at the site's local laboratory) during screening or within 12 weeks before screening. If IGRA test cannot be performed locally, a central laboratory may be used, with prior agreement from the sponsor.

1. An IGRA is strongly recommended for participants with a prior Bacillus Calmette-Guerin (BCG) vaccination, but may be used for any participant. Documentation of IGRA product used and the test result must be in the participant's source documentation if performed locally. Acceptable IGRA products include QuantiFERON TB Gold Plus In-Tube Test.
2. If the results of the IGRA are indeterminate, the test may be repeated, and if a negative result is obtained, enrollment may proceed. In participants with no history of treated active or latent TB, a positive test on repeat will exclude the participant. Participants with a history of active or latent TB infection must follow instructions for "Participants with a prior diagnosis of active or latent TB are excluded unless both of the following criteria are met" in this criterion.
3. Participants with repeat indeterminate IGRA results, with no prior TB history, may be enrolled after consultation with a pulmonary or infectious disease specialist who determines low risk of infection (ie, participant would be acceptable for immunosuppressant [eg, anti-TNF] treatment without additional action). This consultation must be included in source documentation.

Results from a chest x-ray, taken within the 12 weeks before or during screening must show no abnormalities suggestive of active TB infection as determined by a qualified medical specialist.

Participants with a prior diagnosis of active or latent TB are excluded unless both of the following criteria are met:

1. The participant has previously received an adequate course of treatment for either latent (eg, 9 months of isoniazid or an acceptable alternative regimen, in a locale where rates of primary multidrug TB resistance are <5%. Participants from regions with higher rates of primary multidrug TB resistance are excluded) or active (acceptable multidrug regimen) TB infection. Evidence of diagnosis and treatment must be included in source documentation. Consultation with a pulmonary or infectious disease specialist to confirm adequate treatment (ie, participant would be acceptable for immunosuppressant [eg, anti-TNF] treatment without additional action) must be performed during the screening period. The consultation report must be included in source documentation prior to enrollment.
2. A chest x-ray performed within 12 weeks before screening or during screening indicates no evidence of active or recurrent disease, and documentation of interpretation by a qualified medical specialist must be included in source documentation.

* Participants with a pre-existing demyelinating disorder such as multiple sclerosis or new onset seizures, unexplained sensory motor, or cognitive behavioral, neurological deficits, or significant abnormalities noted during screening.
* Participants with any unexplained symptoms suggestive of progressive multifocal leukoencephalopathy (PML) based on the targeted neurological assessment during the screening period.
* Participants with a transplanted organ. Skin grafts to treat pyoderma gangrenosum are allowed.
* Participants with a significant concurrent medical condition at the time of screening or baseline, including, but not limited to, the following:

<!-- -->

1. Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal (except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment will substantially increase the risk to the participant if he or she participates in the study.
2. Cancer or history of cancer or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
3. Presence of acute coronary syndrome (eg, acute myocardial infarction, unstable angina pectoris) within 24 weeks before screening.
4. History of significant cerebrovascular disease within 24 weeks before screening.

- Participants who have had significant trauma or major surgery within 4 weeks before the screening visit, or with any major elective surgery scheduled to occur during the study.

- Participants with evidence of cirrhosis with or without decompensation.

- Participants with primary sclerosing cholangitis.

- Participants with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb).

Note: If a participant tests negative for HBsAg, but positive for HBcAb, the participant would be considered eligible if no presence of hepatitis B virus (HBV) DNA is confirmed by HBV DNA polymerase chain reaction (PCR) reflex testing performed in the central laboratory.
* Participants with chronic hepatitis C virus (HCV) (positive HCV antibody [HCVAb] and HCVRNA).

Note: Participants who are HCVAb positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCVRNA at least 12 weeks prior to baseline]).
* Participants with any of the following abnormalities in hematology and/or serum chemistry profiles during screening.

Note: Screening laboratory tests, if the results are considered by the investigator to be transient and inconsistent with the participant's clinical condition, may be repeated once during the screening period for confirmation. Results must be reviewed for eligibility prior to the screening endoscopy procedure.

<!-- -->

1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels >=3.0×upper limit of normal (ULN).
2. Total bilirubin level >=1.5×ULN or >2.0×ULN if the participant has a known documented history of Gilbert's syndrome.
3. Hemoglobin level <=80 gram per liter (g/L) (8.0 gram per deciliter [g/dL]).
4. Platelet count <=100×10^9 per liter (/L) (100,000 cells per cubic millimeter [mm^3]) or >=1000×10^9/L (1,000,000 cells/mm^3).
5. White blood cell count <=3.5×10^9/L (3500 cells/mm^3).

- Absolute neutrophil count (ANC)<2×10^9/L (2000 cells/mm^3).

- Serum creatinine level >1.5 × ULN or estimated glomerular filtration rate <30 ml/min/1.73m^2 based on the abbreviated Modification of Diet in Renal Disease Study Equation.

Note: If platelet count is <150,000 cells/mm^3, a further evaluation should be performed to rule out cirrhosis, unless another etiology has already been identified.
* Participants with known human immunodeficiency virus (HIV) infection based on documented history, with positive serological test, or positive HIV serologic test at screening, tested at the site's local laboratory in accordance with country requirements or tested at the central laboratory.

Note: A documented negative HIV test within 6 months of screening is acceptable and does not need to be repeated.

- Participants who have, or who have a history of (within 2 years before screening), serious psychiatric disease, alcohol dependency, or substance/drug abuse or dependency of any kind, including abuse of medical marijuana (cannabis).

- Participants with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

- Female participants who are planning to become pregnant during the study period.
* Participants who do not agree to postpone donation of any organ or tissue, including male participants who are planning to bank or donate sperm and female participants who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
* Participants who are investigational site staff members or relatives of those site staff members or Participants who are Shire employees directly involved in the conduct of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
6/10/2020
Sample size
Target
Accrual to date
Final
279
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oklahoma
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Wisconsin
Country [21] 0 0
Argentina
State/province [21] 0 0
Tucumán
Country [22] 0 0
Argentina
State/province [22] 0 0
Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Córdoba
Country [24] 0 0
Belgium
State/province [24] 0 0
Oost-Vlaanderen
Country [25] 0 0
Belgium
State/province [25] 0 0
Vlaams Brabant
Country [26] 0 0
Belgium
State/province [26] 0 0
West-Vlaanderen
Country [27] 0 0
Belgium
State/province [27] 0 0
Mouscron
Country [28] 0 0
Bosnia and Herzegovina
State/province [28] 0 0
Banja Luka
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Sofia-Grad
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Pleven
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Plovdiv
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Ruse
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Sevlievo
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Sofia
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Varna
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Colombia
State/province [38] 0 0
Antioquia
Country [39] 0 0
Colombia
State/province [39] 0 0
Cundinamarca
Country [40] 0 0
Colombia
State/province [40] 0 0
Santander
Country [41] 0 0
Colombia
State/province [41] 0 0
Cali
Country [42] 0 0
Estonia
State/province [42] 0 0
Kohta-Järve
Country [43] 0 0
Estonia
State/province [43] 0 0
Parnu
Country [44] 0 0
Estonia
State/province [44] 0 0
Tallinn
Country [45] 0 0
Greece
State/province [45] 0 0
Attiki
Country [46] 0 0
Greece
State/province [46] 0 0
Patras
Country [47] 0 0
Greece
State/province [47] 0 0
Thessaloniki
Country [48] 0 0
Hungary
State/province [48] 0 0
Bekescsaba
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Hungary
State/province [51] 0 0
Gyula
Country [52] 0 0
Hungary
State/province [52] 0 0
Mohacs
Country [53] 0 0
Hungary
State/province [53] 0 0
Szekszard
Country [54] 0 0
Hungary
State/province [54] 0 0
Szentes
Country [55] 0 0
Hungary
State/province [55] 0 0
Székesfehérvár
Country [56] 0 0
Hungary
State/province [56] 0 0
Veszprém
Country [57] 0 0
Hungary
State/province [57] 0 0
Vác
Country [58] 0 0
Ireland
State/province [58] 0 0
Dublin
Country [59] 0 0
Japan
State/province [59] 0 0
Hokkaidô
Country [60] 0 0
Japan
State/province [60] 0 0
Hyôgo
Country [61] 0 0
Japan
State/province [61] 0 0
Asahikawa
Country [62] 0 0
Japan
State/province [62] 0 0
Chikushino
Country [63] 0 0
Japan
State/province [63] 0 0
Matsumoto-shi
Country [64] 0 0
Japan
State/province [64] 0 0
Oita
Country [65] 0 0
Japan
State/province [65] 0 0
Osaka-shi
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka
Country [67] 0 0
Japan
State/province [67] 0 0
Sakai
Country [68] 0 0
Japan
State/province [68] 0 0
Sakura
Country [69] 0 0
Japan
State/province [69] 0 0
Sendai
Country [70] 0 0
Japan
State/province [70] 0 0
Shimotsuga-gun
Country [71] 0 0
Japan
State/province [71] 0 0
Takatsuki
Country [72] 0 0
Japan
State/province [72] 0 0
Tokyo
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Gang'weondo
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Gyeonggido
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Busan
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Daegu
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Incheon
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul
Country [79] 0 0
Lebanon
State/province [79] 0 0
Beirut
Country [80] 0 0
Lebanon
State/province [80] 0 0
Saida
Country [81] 0 0
Mexico
State/province [81] 0 0
Distrito Federal
Country [82] 0 0
Mexico
State/province [82] 0 0
Morelos
Country [83] 0 0
Mexico
State/province [83] 0 0
Yucatán
Country [84] 0 0
Mexico
State/province [84] 0 0
Aguascalientes
Country [85] 0 0
Mexico
State/province [85] 0 0
Cuautitlan Izcalli
Country [86] 0 0
Mexico
State/province [86] 0 0
Durango
Country [87] 0 0
Mexico
State/province [87] 0 0
Monterrey
Country [88] 0 0
Mexico
State/province [88] 0 0
Tlalnepantla De Baz
Country [89] 0 0
Mexico
State/province [89] 0 0
Zapopan, Jalisco
Country [90] 0 0
New Zealand
State/province [90] 0 0
Auckland
Country [91] 0 0
New Zealand
State/province [91] 0 0
South Island
Country [92] 0 0
New Zealand
State/province [92] 0 0
Wellington
Country [93] 0 0
New Zealand
State/province [93] 0 0
Hamilton
Country [94] 0 0
Portugal
State/province [94] 0 0
Braga
Country [95] 0 0
Portugal
State/province [95] 0 0
Guimarães
Country [96] 0 0
Portugal
State/province [96] 0 0
Lisboa
Country [97] 0 0
Portugal
State/province [97] 0 0
Portimão
Country [98] 0 0
Portugal
State/province [98] 0 0
Setubal
Country [99] 0 0
Slovakia
State/province [99] 0 0
Bratislava
Country [100] 0 0
Slovakia
State/province [100] 0 0
Nitra
Country [101] 0 0
Slovakia
State/province [101] 0 0
Presov
Country [102] 0 0
Spain
State/province [102] 0 0
Córdoba
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Pontevedra
Country [105] 0 0
Spain
State/province [105] 0 0
Barcelona
Country [106] 0 0
Spain
State/province [106] 0 0
Huelva
Country [107] 0 0
Spain
State/province [107] 0 0
Sevilla
Country [108] 0 0
Spain
State/province [108] 0 0
Valencia
Country [109] 0 0
Switzerland
State/province [109] 0 0
Zürich (de)
Country [110] 0 0
Turkey
State/province [110] 0 0
Istanbul
Country [111] 0 0
Turkey
State/province [111] 0 0
Mersin
Country [112] 0 0
Ukraine
State/province [112] 0 0
Chernivets'ka Oblast
Country [113] 0 0
Ukraine
State/province [113] 0 0
Kharkivs'ka Oblast
Country [114] 0 0
Ukraine
State/province [114] 0 0
Vinnyts'ka Oblast
Country [115] 0 0
Ukraine
State/province [115] 0 0
Dnipro
Country [116] 0 0
Ukraine
State/province [116] 0 0
Kharkiv
Country [117] 0 0
Ukraine
State/province [117] 0 0
Kherson
Country [118] 0 0
Ukraine
State/province [118] 0 0
Kryvyi Rih
Country [119] 0 0
Ukraine
State/province [119] 0 0
Kyiv
Country [120] 0 0
Ukraine
State/province [120] 0 0
Lviv
Country [121] 0 0
Ukraine
State/province [121] 0 0
Odesa
Country [122] 0 0
Ukraine
State/province [122] 0 0
Uzhhorod
Country [123] 0 0
Ukraine
State/province [123] 0 0
Vinnytsia
Country [124] 0 0
Ukraine
State/province [124] 0 0
Zaporizhzhia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Shire
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Shire
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03259308